Is Fulgent Genetics a good stock to buy?
The P/E ratio of Fulgent Genetics is 3.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 18.71. Fulgent Genetics has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Is Fulgent Genetics a buy right now?
How much is a share of Fulgent worth?
One share of FLGT stock can currently be purchased for approximately $69.86. How much money does Fulgent Genetics make? Fulgent Genetics has a market capitalization of $2.08 billion and generates $421.71 million in revenue each year. The company earns $214.31 million in net income (profit) each year or $19.20 on an earnings per share basis.
How did Fulgent Genetics'shares rise 93% last year?
Shares of diagnostic testing company Fulgent Genetics (NASDAQ: FLGT) were up 93% last year, according to S&P Global Market Intelligence. The unpredictability of COVID took shareholders on a journey through several peaks and valleys on the way to that gain.
Who sold flgt stock in the last quarter?
FLGT stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Nepsis Inc., Capital Fund Management S.A., Harel Insurance Investments & Financial Services Ltd., Ensign Peak Advisors Inc, First Trust Advisors LP, Cutler Group LP, and Advisor Group Holdings Inc..
See more
Is Fulgent Genetics a good buy?
Valuation metrics show that Fulgent Genetics, Inc. may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of FLGT, demonstrate its potential to outperform the market.
Will FLGT go up?
The 2 analysts offering 12-month price forecasts for Fulgent Genetics Inc have a median target of 91.00, with a high estimate of 112.00 and a low estimate of 70.00. The median estimate represents a +56.95% increase from the last price of 57.98.
Who owns Fulgent Genetics?
Ming HsiehMing Hsieh is the founder, president, CEO and chair of Fulgent Genetics, a genetic testing technology company. He started Fulgent Genetics in 2011 and took the company public in 2016.
How much cash does Fulgent Genetics have?
While it is always sensible to investigate a company's debt, in this case Fulgent Genetics has US$564.0m in net cash and a decent-looking balance sheet.
Is fulgent a buy or sell?
Fulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.
What sector is fulgent genetics in?
technology companyFulgent Genetics, Inc. operates as a technology company. The Company develops a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes.
Does BlackRock own fulgent?
Institutional investors purchased a net $1.0 million shares of FLGT during the quarter ended June 2019....Top 10 Owners of Fulgent Genetics Inc.StockholderBlackRock Fund AdvisorsShares owned3,085,139Total value ($)169,312,428Shares bought / sold-22,7949 more columns
When did fulgent Genetics go public?
When did Fulgent go public? Fulgent's common stock began trading on the NASDAQ Global Market on September 28, 2016.
Is Fulgent Genetics a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1...
When is Fulgent Genetics' next earnings date?
Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Fulge...
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics, Inc. (NASDAQ:FLGT) released its quarterly earnings data on Tuesday, May, 3rd. The company reported $5.08 earnings per share for t...
What guidance has Fulgent Genetics issued on next quarter's earnings?
Fulgent Genetics updated its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of f...
What price target have analysts set for FLGT?
2 equities research analysts have issued 12 month price targets for Fulgent Genetics' stock. Their forecasts range from $65.00 to $125.00. On avera...
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the following people: Mr. Ming Hsieh , Chairman, CEO & Pres (Age 66, Pay $5.66M) Mr. Paul Kim , Chie...
Who are some of Fulgent Genetics' key competitors?
Some companies that are related to Fulgent Genetics include Guardant Health (GH) , Natera (NTRA) , Elekta AB (publ) (EKTAY) , CareDx (CDNA) ,...
What other stocks do shareholders of Fulgent Genetics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA) , CR...
When did Fulgent Genetics IPO?
(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per...
Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Call Transcript
Image source: The Motley Fool. Fulgent Genetics, Inc. (NASDAQ: FLGT)Q4 2021 Earnings CallFeb 23, 2022, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the fourth quarter 2021 Fulgent Genetics earnings conference call.
Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?
In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.
4 Best Stocks With High Net Income Ratio to Grab Today
OPBK, BBW, EVRI, and FLGT qualified the screen for stocks with a high net income ratio.
Nasdaq Global Market
Fulgent Genetics is a technology company that provides comprehensive diagnostic genetic testing using its proprietary platform, which integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes.
Environmental, Social, and Governance Rating
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Business Summary
Fulgent Genetics is a technology company that provides comprehensive diagnostic genetic testing using its proprietary platform, which integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes.
Signals & Forecast
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 5.54%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices.
Support, Risk & Stop-loss
Fulgent Genetics Inc finds support from accumulated volume at $63.50 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Fulgent Genetics Inc stock A Buy?
Fulgent Genetics Inc holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are positive as most new trades are buy in Fulgent Genetics Inc
In the last 100 trades there were 770.44 thousand shares bought and 1.15 million shares sold. The last trade was done 7 days ago by Kim Paul who sold 806 shares. For the period there is more stocks sold than bought, but the most of the latest transactions are buy. This can indicate renewed interest by the insider, but also stock options expiring
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What happened
Shares of coronavirus testing company Fulgent Genetics ( FLGT 1.28% ) are down 16.2% to $91.98 apiece as of 10:30 a.m. EDT. During the second quarter of 2021, reported yesterday, the company's revenue grew by a stunning 790% year over year to $153.6 million. Simultaneously, its earnings increased 24-fold to $79.8 million.
So what
Fulgent derives the overwhelming majority of its revenue from coronavirus testing. Due to the rampant spread of the delta variant, daily COVID-19 cases in the U.S. spiked to more than 235,000 on Aug. 9, almost on par with January levels. However, the success of vaccination campaigns ensured that COVID-19-related deaths only saw a tiny spike.
Now what
Fulgent stock is incredibly cheap right now at just 6.5 times earnings. Its enterprise value is also far lower (the lower, the better) than its market cap of $2.773 billion due to the company having no debt and more than $773 million in cash on hand.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Premium Research for FLGT
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Company Summary
Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information.
